Medical Pharmacology: Chapter 32 — Hypothalamic Pharmacology -- Module 2

Chapter 32 — Hypothalamic Pharmacology — Module 2 — GnRH Analogs in Clinical Practice

1. A 74-year-old man presents with newly diagnosed metastatic prostate cancer. Imaging shows multiple lumbar vertebral metastases with early epidural extension at L3. He has moderate back pain but no neurological deficit. The oncology team needs to begin androgen deprivation therapy promptly. Which of the following initiation strategies is most appropriate to avoid precipitating a clinical catastrophe in this patient?

A) Begin leuprolide depot alone, because the slow drug release from the depot formulation prevents any meaningful testosterone surge in patients with vertebral metastases
B) Begin leuprolide depot together with calcium and vitamin D supplementation alone, deferring any anti-androgen because bone-protective supplementation mitigates the risk of spinal cord compression during the flare
C) Begin a GnRH antagonist such as degarelix, or alternatively a GnRH agonist with anti-androgen flare coverage begun before the agonist, because agonist monotherapy produces a testosterone flare that risks spinal cord compression in a patient with epidural vertebral disease
D) Begin leuprolide depot monotherapy and add an anti-androgen only if the patient develops new neurological symptoms during the first 2 weeks of therapy
E) Defer all androgen deprivation therapy and proceed directly to bilateral orchiectomy, because medical castration is contraindicated in any patient with vertebral metastases owing to unavoidable flare risk

ANSWER: C

Rationale:

This patient has epidural extension of vertebral metastatic disease, placing him at high risk for spinal cord compression if a testosterone flare occurs. GnRH agonists produce a testosterone surge of 50 to 80% above baseline during the first 1 to 2 weeks of therapy because initial receptor activation drives an LH and FSH surge before downregulation occurs. In a patient with epidural disease, this flare can precipitate cord compression — a neurological emergency. The two appropriate strategies are: (1) use a GnRH antagonist such as degarelix (or oral relugolix), which suppresses testosterone immediately with no flare, achieving castrate levels within days; or (2) if an agonist is used, provide anti-androgen flare coverage (for example bicalutamide 50 mg daily) begun 7 to 14 days before the first depot injection and continued for about 4 weeks to block androgen receptor activation during the surge. Given the urgency and high risk here, an antagonist is often preferred.

Option A: Option A is incorrect because all GnRH agonist depot formulations produce a testosterone flare of similar magnitude; the slow-release depot kinetics maintain sustained suppression after downregulation but do not prevent the initial receptor activation phase responsible for the surge.
Option B: Option B is incorrect because calcium and vitamin D supplementation protects bone mineral density over the long term but does nothing to prevent the acute testosterone flare or the resulting risk of cord compression; it is not a substitute for anti-androgen coverage or antagonist therapy.
Option D: Option D is incorrect because waiting for new neurological symptoms before adding an anti-androgen is dangerous — spinal cord compression can produce rapid, irreversible deficits, and the flare must be prevented prospectively, not treated reactively.
Option E: Option E is incorrect because medical castration is not contraindicated in patients with vertebral metastases; the flare risk is managed by choosing an antagonist or by providing anti-androgen coverage with an agonist, and orchiectomy is not a mandatory alternative.

2. A 70-year-old man with metastatic prostate cancer and a solitary thoracic vertebral metastasis is scheduled to start leuprolide 22.5 mg IM depot. His oncologist elects to use anti-androgen flare coverage rather than switch to an antagonist. The patient will receive his first leuprolide injection at his appointment 10 days from now. Which of the following is the most appropriate way to provide flare coverage?

A) Start bicalutamide 50 mg daily now, 10 days before the first leuprolide injection, and continue it for approximately 4 weeks after the injection, so that androgen receptor blockade is established before the testosterone surge begins
B) Start bicalutamide 50 mg daily on the same day as the first leuprolide injection, because anti-androgen and agonist must begin simultaneously to coordinate their pharmacodynamic effects
C) Start bicalutamide 50 mg daily 4 weeks after the first leuprolide injection, once the testosterone surge has resolved, to consolidate suppression
D) Administer a single dose of bicalutamide 150 mg on the day of the leuprolide injection only, because a one-time loading dose provides sufficient androgen receptor blockade throughout the entire flare period
E) Continue bicalutamide 50 mg daily indefinitely alongside leuprolide as combined androgen blockade, because lifelong anti-androgen co-administration is required whenever flare coverage is initiated

ANSWER: A

Rationale:

Anti-androgen flare coverage must be established before the testosterone surge begins. The correct approach is to start bicalutamide 50 mg daily 7 to 14 days before the first GnRH agonist depot injection and continue it for approximately 4 weeks after the injection. In this patient, starting bicalutamide now — 10 days before the scheduled injection — ensures that androgen receptor (AR) blockade is in place when the LH-driven testosterone surge occurs during the first 1 to 2 weeks after the agonist is given. Bicalutamide competitively blocks the AR, preventing testosterone and dihydrotestosterone from stimulating tumor growth and bone pain during the flare.

Option B: Option B is incorrect because starting the anti-androgen on the same day as the agonist does not establish AR blockade before the surge begins; the flare can start within days, and AR blockade should already be present at that point.
Option C: Option C is incorrect because starting the anti-androgen 4 weeks after the injection completely misses the flare window — by then the surge has already occurred and any risk of disease flare would already have been realized.
Option D: Option D is incorrect because a single dose of bicalutamide does not provide sustained AR blockade across the 1- to 2-week flare period; daily dosing throughout the flare period is required.
Option E: Option E is incorrect because anti-androgen coverage for flare prevention is intended to be time-limited (approximately 4 weeks); continuous indefinite combined androgen blockade provides only marginal benefit over agonist alone while substantially increasing adverse effects and is not the standard approach to flare coverage.

3. A 68-year-old man presents with metastatic prostate cancer, severe bone pain from diffuse skeletal metastases, and bladder outlet obstruction from local tumor extension causing acute urinary retention. The urology team needs to achieve testosterone suppression as rapidly as possible to relieve symptoms. Which of the following agents best meets the clinical need for the fastest onset of castrate testosterone, and why?

A) Leuprolide depot, because GnRH agonists achieve castrate testosterone within 24 to 72 hours of the first injection, faster than any antagonist
B) Goserelin implant, because the subcutaneous implant releases drug more rapidly than intramuscular depot formulations and achieves castration within 3 days
C) Triptorelin depot, because its higher receptor binding affinity compared with leuprolide produces immediate castration without a flare
D) Degarelix, because as a GnRH antagonist it suppresses LH and FSH immediately without receptor activation, achieving castrate testosterone in more than 96% of patients within about 3 days and producing no testosterone flare
E) Bicalutamide monotherapy, because direct androgen receptor blockade lowers serum testosterone to castrate levels faster than agents acting at the pituitary

ANSWER: D

Rationale:

When the clinical situation demands the most rapid possible testosterone suppression — as in this patient with severe symptomatic disease — a GnRH antagonist is the agent of choice. Degarelix competitively and reversibly blocks the GnRH receptor on pituitary gonadotrophs, immediately suppressing LH and FSH without any initial receptor activation. It achieves castrate testosterone levels (below 50 ng/dL) in more than 96% of patients within about 3 days of the loading dose, with no testosterone flare. This rapid, flare-free onset is exactly what is needed to relieve symptoms quickly and safely.

Option A: Option A is incorrect because GnRH agonists such as leuprolide take 3 to 4 weeks to achieve castrate testosterone and produce a flare during the first 1 to 2 weeks; they do not achieve castration within 24 to 72 hours — that rapid timeframe describes antagonists, not agonists.
Option B: Option B is incorrect because goserelin is a GnRH agonist; despite its subcutaneous implant formulation, it shares the agonist class profile of delayed castration (about 21 to 28 days) and an initial flare, and it does not achieve castration within 3 days.
Option C: Option C is incorrect because triptorelin is also a GnRH agonist; its modestly higher receptor binding affinity does not eliminate the flare or produce immediate castration — it shares the delayed-onset, flare-producing profile of the agonist class.
Option E: Option E is incorrect because bicalutamide blocks the androgen receptor but does not lower serum testosterone; it actually tends to raise serum testosterone through loss of negative feedback, so it cannot produce castrate testosterone levels and is not a substitute for pituitary-level suppression.

4. A 33-year-old woman with moderate endometriosis-associated pain has a maternal history of early osteoporosis and a baseline DEXA showing low-normal bone mineral density. Her gynecologist plans to use elagolix and wants to minimize the risk of further bone loss while still controlling her pain. Which of the following dosing strategies is most consistent with this clinical goal?

A) Elagolix 200 mg twice daily, because the higher dose achieves near-complete estradiol suppression that is required for any meaningful reduction in endometriosis pain
B) Elagolix 150 mg once daily, because this dose produces partial estradiol suppression to early follicular phase levels, reducing pain while preserving some ovarian estradiol output and substantially attenuating bone mineral density loss; it can also be used for up to 24 months
C) Leuprolide depot 3.75 mg monthly without add-back therapy, because depot agonists provide more titratable estradiol control than oral antagonists in patients at risk for bone loss
D) Elagolix 200 mg twice daily with no add-back therapy for 12 months, because this regimen is specifically designed to protect bone in patients with a family history of osteoporosis
E) Elagolix 150 mg once daily combined with a GnRH agonist depot, because dual GnRH-axis suppression reduces the dose-related bone loss seen with either agent alone

ANSWER: B

Rationale:

Elagolix has a dose-dependent pharmacodynamic profile that allows tailoring the depth of estrogen suppression to the clinical situation. The 150 mg once-daily dose produces partial estradiol suppression to approximately early follicular phase levels (about 12 to 73 pg/mL), which reduces endometriosis pain while preserving some ovarian estradiol output. Because estradiol is not driven to castrate levels, bone mineral density (BMD) loss is substantially attenuated compared with deeper suppression, and the 150 mg once-daily dose can be used for up to 24 months. This makes it the most appropriate choice for a patient at elevated risk of bone loss who still needs pain control.

Option A: Option A is incorrect because meaningful reduction in endometriosis pain does not require the 200 mg twice-daily dose; the 150 mg once-daily dose provides clinically useful pain relief, and the higher dose produces near-complete suppression with greater BMD loss, which is precisely what should be avoided in this patient.
Option C: Option C is incorrect because GnRH agonist depots produce profound, non-titratable estradiol suppression to castrate levels — they are not more titratable than elagolix, and used without add-back they cause more bone loss, the opposite of the clinical goal.
Option D: Option D is incorrect because elagolix 200 mg twice daily produces near-complete estradiol suppression with greater BMD loss and is limited to 6 months without add-back (up to 12 months with add-back); it is not a bone-protective regimen and is not designed to protect bone in patients with a family history of osteoporosis.
Option E: Option E is incorrect because combining elagolix with a GnRH agonist depot is not a recognized regimen; layering two agents that both suppress the gonadal axis would deepen, not lessen, estrogen deprivation and bone loss, and there is no rationale for dual suppression.

5. A 72-year-old man with advanced prostate cancer is well controlled on relugolix 120 mg once daily. He develops a respiratory infection, and a covering physician is about to prescribe clarithromycin. The oncology pharmacist reviews the medication list and intervenes. Which of the following best describes the basis for the pharmacist's concern and the appropriate management?

A) Clarithromycin induces CYP3A4, which would accelerate relugolix metabolism and cause loss of testosterone suppression; the relugolix dose should be doubled during the antibiotic course
B) Clarithromycin and relugolix have no clinically significant interaction; the pharmacist's concern is unfounded and the antibiotic can be prescribed without any change
C) Clarithromycin inhibits CYP3A4, the major enzyme responsible for relugolix metabolism, markedly increasing relugolix exposure; relugolix should be held entirely during the antibiotic course
D) Clarithromycin displaces relugolix from plasma protein binding sites, transiently increasing free relugolix; no action is needed because the effect is short-lived
E) Clarithromycin is a strong P-glycoprotein inhibitor, and because relugolix is a P-glycoprotein substrate, co-administration can increase relugolix exposure substantially; the combination should be avoided where possible, or relugolix managed per labeling, and an alternative antibiotic considered

ANSWER: E

Rationale:

Relugolix is a substrate of P-glycoprotein (P-gp), and its disposition is governed by P-gp-mediated transport rather than by CYP3A4 metabolism. Clarithromycin is a strong P-gp inhibitor. When co-administered, clarithromycin reduces P-gp-mediated efflux of relugolix, increasing relugolix absorption and systemic exposure (strong P-gp inhibitors can raise relugolix exposure up to about 4-fold). This raises the risk of adverse effects from excessive drug exposure. The appropriate management is to avoid the combination where possible, follow product labeling for any required dose adjustment or timing separation, and consider an alternative antibiotic that does not inhibit P-gp. Other strong P-gp inhibitors that pose the same concern include amiodarone, itraconazole, and verapamil.

Option A: Option A is incorrect because clarithromycin inhibits rather than induces relevant pathways, and relugolix is not significantly metabolized by CYP3A4; doubling the dose would be both mechanistically wrong and dangerous.
Option B: Option B is incorrect because there is a clinically significant P-gp-mediated interaction between clarithromycin and relugolix; dismissing the pharmacist's concern could lead to harmful overexposure.
Option C: Option C is incorrect because relugolix is not a major CYP3A4 substrate; the clinically relevant mechanism is P-gp inhibition, not CYP3A4 inhibition. This distinguishes relugolix from elagolix, which is a CYP3A4 substrate.
Option D: Option D is incorrect because the interaction is not based on plasma protein binding displacement; it is a transporter-mediated interaction at P-gp that increases relugolix exposure and is not a trivial, short-lived effect.

6. A 36-year-old woman with severe endometriosis-associated pain is being treated with elagolix 200 mg twice daily with norethindrone acetate add-back. She is diagnosed with esophageal candidiasis and the consulting team proposes oral ketoconazole. Her gynecologist is asked to weigh in. Which of the following is the most appropriate assessment?

A) Ketoconazole and elagolix do not interact because elagolix is eliminated primarily by renal excretion of unchanged drug; the antifungal can be prescribed without modification
B) Ketoconazole induces CYP3A4 and would reduce elagolix exposure, risking loss of pain control; the elagolix dose should be increased during the antifungal course
C) Ketoconazole is a strong CYP3A4 inhibitor, and because elagolix is a major CYP3A4 substrate, co-administration substantially increases elagolix exposure; the elagolix 200 mg twice-daily dose is contraindicated with strong CYP3A4 inhibitors, so an alternative antifungal should be selected or the elagolix regimen reconsidered
D) The interaction is clinically unimportant because norethindrone acetate add-back therapy neutralizes any increase in elagolix plasma concentration
E) Ketoconazole increases elagolix clearance through P-glycoprotein induction in the intestine, so a higher elagolix dose is needed to maintain efficacy during co-administration

ANSWER: C

Rationale:

Elagolix is metabolized primarily by CYP3A4. Ketoconazole is one of the most potent CYP3A4 inhibitors in clinical use. Co-administration substantially increases elagolix plasma concentrations, and the elagolix 200 mg twice-daily dose is specifically contraindicated with strong CYP3A4 inhibitors because the resulting exposure can reach potentially harmful concentrations. The appropriate action is to select an alternative antifungal that does not strongly inhibit CYP3A4, or to reconsider the elagolix regimen in consultation with the prescriber.

Option A: Option A is incorrect because elagolix is not eliminated primarily by renal excretion of unchanged drug; it undergoes extensive hepatic CYP3A4 metabolism, which is exactly why the ketoconazole interaction is significant.
Option B: Option B is incorrect because ketoconazole inhibits, not induces, CYP3A4; it increases rather than decreases elagolix exposure, so raising the elagolix dose would compound the toxicity risk.
Option D: Option D is incorrect because add-back therapy with norethindrone acetate addresses hypoestrogenic adverse effects (such as bone loss and vasomotor symptoms); it does not alter elagolix pharmacokinetics or neutralize a CYP3A4-mediated increase in elagolix concentration.
Option E: Option E is incorrect because ketoconazole does not induce intestinal P-glycoprotein to increase elagolix clearance; the dominant and clinically relevant mechanism here is strong CYP3A4 inhibition that raises elagolix exposure, making the 200 mg twice-daily dose contraindicated.

7. A 38-year-old woman has been on leuprolide depot 3.75 mg monthly for endometriosis for 4 months with excellent pain control, but she reports disabling hot flashes and a repeat DEXA shows a 4% decline in lumbar spine bone mineral density. She wishes to continue effective treatment. Which of the following management strategies best addresses both her bone loss and her symptoms while preserving pain control?

A) Add add-back therapy, such as norethindrone acetate 5 mg daily, or low-dose estrogen plus a progestin, to raise estradiol into the approximately 20 to 40 pg/mL window — high enough to protect bone and reduce hot flashes but low enough to keep endometriosis suppressed — allowing continued therapy beyond 6 months
B) Discontinue all therapy immediately, because any continuation of GnRH agonist treatment after detectable bone loss is contraindicated regardless of add-back therapy
C) Double the leuprolide dose to deepen suppression, which will paradoxically reduce bone loss by more completely shutting down the inflammatory activity of endometriosis implants
D) Add high-dose conjugated estrogen sufficient to raise estradiol above 60 pg/mL, because only supraphysiologic estrogen levels can reverse established bone mineral density loss
E) Switch to a GnRH antagonist such as degarelix, because antagonists do not cause the hypoestrogenic bone loss seen with agonists

ANSWER: A

Rationale:

This patient is experiencing the predictable hypoestrogenic adverse effects of GnRH agonist therapy — bone mineral density (BMD) loss and vasomotor symptoms — while benefiting from good pain control. The correct strategy is add-back therapy, which applies the estrogen threshold principle: endometriosis implants require estradiol above approximately 20 pg/mL to grow, while bone protection requires estradiol above approximately 30 to 40 pg/mL. Add-back therapy (for example, norethindrone acetate 5 mg daily alone, or low-dose estrogen plus a progestin) is dosed to place estradiol in the 20 to 40 pg/mL window — sufficient to protect bone and relieve hot flashes while remaining below the threshold that would reactivate endometriosis. Add-back allows continuation of therapy beyond the 6-month limit that applies to agonist use without add-back, and importantly, appropriately dosed add-back does not significantly reduce pain control.

Option B: Option B is incorrect because continuation of GnRH agonist therapy after detectable bone loss is not contraindicated; the standard solution is precisely to add add-back therapy, which permits safe continuation.
Option C: Option C is incorrect because doubling the leuprolide dose would deepen hypoestrogenism and worsen, not reduce, bone loss; estradiol is already suppressed to castrate levels, and further suppression cannot lower it meaningfully but does nothing to protect bone.
Option D: Option D is incorrect because raising estradiol above 60 pg/mL exceeds the threshold for endometriosis stimulation (approximately 20 pg/mL) and would risk reactivating the implants and recurrent pain; the add-back target is the 20 to 40 pg/mL window, not supraphysiologic levels.
Option E: Option E is incorrect because GnRH antagonists also suppress estradiol and produce hypoestrogenic bone loss when used to treat endometriosis; switching from an agonist to degarelix does not avoid bone loss, since the mechanism of bone loss is estrogen deprivation shared by both classes.

8. An 8-year-old girl with central precocious puberty has been receiving leuprolide depot 7.5 mg IM every 4 weeks for 6 months. Her breast development has continued to progress and her growth velocity remains accelerated. The pediatric endocrinologist orders a GnRH stimulation test, which shows a stimulated LH peak of 4.5 IU/L (IU per liter) at 40 minutes. Which of the following best interprets this result and indicates the appropriate next step?

A) The stimulated LH of 4.5 IU/L confirms adequate suppression; the continued progression reflects peripheral precocious puberty and the leuprolide should be discontinued
B) The stimulated LH of 4.5 IU/L confirms adequate suppression, and the clinical progression is expected during the first year of therapy and requires no change
C) The result cannot be interpreted because GnRH stimulation testing is not valid for assessing suppression in children on depot agonist therapy; a random unstimulated LH should be used instead
D) The stimulated LH of 4.5 IU/L is above the target threshold of below 2 IU/L that confirms adequate HPG axis suppression; together with continued clinical progression, this indicates inadequate suppression, and the dose or dosing interval should be intensified
E) The stimulated LH of 4.5 IU/L indicates oversuppression of the HPG axis, and the leuprolide dose should be reduced to allow controlled pubertal progression

ANSWER: D

Rationale:

In central precocious puberty (CPP), adequacy of hypothalamic-pituitary-gonadal (HPG) axis suppression on GnRH agonist depot therapy is confirmed by demonstrating a stimulated LH peak below 2 IU/L (IU per liter) after GnRH or GnRH agonist stimulation, typically measured at 30 to 60 minutes. This patient's stimulated LH of 4.5 IU/L is above that threshold, indicating inadequate suppression. This biochemical finding is corroborated by the clinical picture: continued breast development and persistently accelerated growth velocity both signal ongoing pubertal activation. The appropriate response is to intensify therapy — increase the dose or shorten the dosing interval — and then reconfirm suppression with repeat stimulation testing.

Option A: Option A is incorrect because a stimulated LH of 4.5 IU/L does not confirm adequate suppression (the target is below 2 IU/L), and the picture is consistent with inadequately suppressed central precocious puberty, not peripheral precocious puberty; discontinuing leuprolide would worsen the situation.
Option B: Option B is incorrect because a stimulated LH of 4.5 IU/L is above the suppression target and the continued progression is a sign of treatment failure, not an expected and acceptable finding requiring no change.
Option C: Option C is incorrect because GnRH (or GnRH agonist) stimulation testing is the standard and valid method to confirm suppression adequacy in children on depot agonist therapy; a stimulated peak LH below 2 IU/L is the accepted criterion.
Option E: Option E is incorrect because a stimulated LH of 4.5 IU/L reflects insufficient, not excessive, suppression; reducing the dose would further worsen the inadequate control and accelerate pubertal progression.

9. A 71-year-old man with metastatic prostate cancer has received leuprolide depot every 3 months for 2 years. His PSA, previously undetectable, has risen to 2.6 ng/mL, and a testosterone level drawn before his next scheduled injection is 68 ng/dL. The clinic notes that his injections have all been given in the same site, which now feels firm and fibrotic. Which of the following is the most appropriate interpretation and next step?

A) The testosterone of 68 ng/dL is acceptable, and the PSA rise should be managed by adding an anti-androgen to block residual androgen receptor signaling without changing the GnRH agonist
B) This is non-castrate testosterone on depot agonist therapy, likely from impaired drug absorption at the fibrotic injection site; the appropriate steps include verifying and correcting injection technique, rotating injection sites, and considering a switch to a GnRH antagonist such as degarelix or relugolix, which maintain castrate levels more consistently
C) The testosterone of 68 ng/dL confirms the development of castration-resistant prostate cancer, and the GnRH agonist should be stopped because it is no longer providing benefit
D) The testosterone of 68 ng/dL indicates the patient has developed antibodies against leuprolide; he should be switched to a different GnRH agonist such as goserelin to bypass the immune response
E) The result reflects laboratory error, since depot agonist therapy reliably maintains testosterone below 50 ng/dL in essentially all patients; the test should simply be repeated and no clinical action taken

ANSWER: B

Rationale:

A serum testosterone of 68 ng/dL is above the castration threshold (below 50 ng/dL by traditional criteria, below 20 ng/dL by newer guidelines) and constitutes non-castrate testosterone on depot agonist therapy, occurring in roughly 4 to 13% of patients. The combination of a rising PSA and a fibrotic, repeatedly used injection site points to impaired drug absorption from injection site fibrosis as a likely cause; other causes include incorrect injection technique and end-of-dose escape. The appropriate steps are to verify and correct injection technique, rotate to fresh injection sites, and consider switching to a GnRH antagonist (degarelix or relugolix), which maintains castrate testosterone more consistently.

Option A: Option A is incorrect because a testosterone of 68 ng/dL is not acceptable by any castration standard; simply adding an anti-androgen without restoring castrate testosterone leaves the underlying suppression failure unaddressed.
Option C: Option C is incorrect because castration-resistant prostate cancer is defined by disease progression despite confirmed castrate testosterone levels; with a testosterone of 68 ng/dL, castration has not been achieved, so this does not meet the definition of castration resistance, and the agonist should not be abandoned before adequate suppression is restored.
Option D: Option D is incorrect because clinically significant neutralizing antibodies against leuprolide causing treatment failure are not an established mechanism of non-castrate testosterone; the far more likely explanation is a pharmacokinetic delivery problem at the fibrotic site.
Option E: Option E is incorrect because non-castrate testosterone on depot therapy is a recognized clinical entity, not merely laboratory error; dismissing the result and taking no action would miss a correctable cause of inadequate suppression.

10. A 76-year-old man with metastatic prostate cancer is about to start GnRH agonist therapy. He is being treated for recurrent atrial fibrillation with sotalol and recently completed a course of levofloxacin for pneumonia, and he takes ondansetron intermittently for nausea. His baseline QTc is 470 ms. Which of the following best describes the cardiovascular risk and the most appropriate management before initiating androgen deprivation therapy?

A) GnRH agonist therapy has no effect on the QT interval; therefore the only relevant cardiac consideration in this patient is his atrial fibrillation, and no additional QT-related monitoring is needed before starting therapy
B) The patient's QT-prolonging medications should all be continued unchanged, because the brief flare phase of GnRH agonist therapy is the only period of QT risk and it resolves once castrate testosterone is achieved
C) A baseline QTc of 470 ms is reassuringly normal and requires no further evaluation; GnRH agonist therapy and the current medications can be continued together without ECG follow-up
D) The QT risk in this patient comes solely from a direct effect of the GnRH agonist peptide on cardiac ion channels; switching to a GnRH antagonist would eliminate the QT concern entirely
E) Androgen deprivation therapy prolongs the QTc through testosterone suppression, and this adds to the effects of sotalol, a fluoroquinolone, and ondansetron — all QT-prolonging agents; with a baseline QTc of 470 ms this is a high-risk combination warranting cardiology input, a baseline ECG, review of the QT-prolonging medications, and repeat ECG after initiation

ANSWER: E

Rationale:

Androgen deprivation therapy (ADT)-induced testosterone suppression prolongs the cardiac action potential and increases the corrected QT interval (QTc) by roughly 10 to 20 milliseconds on average. This baseline prolongation is additive to that of concurrent QT-prolonging drugs. This patient stacks several risks: sotalol (a potent QT-prolonging antiarrhythmic), a recently completed fluoroquinolone (levofloxacin), ondansetron (a QT-prolonging antiemetic), and an already elevated baseline QTc of 470 ms. The appropriate management is cardiology consultation, a baseline ECG, careful review and possible modification of the QT-prolonging medications, and repeat ECG after ADT initiation. Patients with a baseline QTc above 500 ms or congenital long QT syndrome should not receive GnRH analogs without cardiology input.

Option A: Option A is incorrect because GnRH agonist therapy does affect the QT interval — through testosterone suppression — so QT-related monitoring is relevant in this high-risk patient.
Option B: Option B is incorrect because the QT-prolonging effect of ADT is sustained throughout treatment, not limited to the flare phase; sustained hypogonadism maintains QTc prolongation, so the concurrent QT-prolonging drugs cannot simply be ignored.
Option C: Option C is incorrect because a baseline QTc of 470 ms is already prolonged (above the typical upper limit of approximately 440 ms in men) and, combined with multiple QT-prolonging drugs, warrants active management and ECG follow-up rather than no evaluation.
Option D: Option D is incorrect because the QT effect of GnRH analogs is mediated by testosterone suppression, a class effect shared by agonists and antagonists; switching to an antagonist does not eliminate the QT concern because antagonists suppress testosterone just as agonists do.

11. A 73-year-old man has been on continuous leuprolide depot for prostate cancer for 14 months. He takes calcium and vitamin D. His baseline DEXA showed a femoral neck T-score of -1.6, and a repeat scan now shows -2.2. He has a history of a wrist fracture after a minor fall 2 years ago. Which of the following is the most appropriate bone-protective management?

A) Continue calcium and vitamin D alone, since these supplements are sufficient to prevent fractures in all men on androgen deprivation therapy regardless of baseline bone density
B) Stop the leuprolide and begin intermittent androgen deprivation therapy, because treatment holidays alone will fully restore bone mineral density without the need for any bone-targeted pharmacotherapy
C) Initiate a bone-protective agent such as zoledronic acid 4 mg intravenously every 12 months or denosumab 60 mg subcutaneously every 6 months, because this patient has multiple risk factors — a low baseline T-score, a prior fragility fracture, progressive bone loss on supplementation, and prolonged androgen deprivation therapy
D) Begin low-dose testosterone supplementation to protect bone, accepting a small risk of disease progression because the bone benefit outweighs the oncologic risk
E) Defer any additional bone therapy until the patient sustains a vertebral or hip fracture, since prophylactic treatment before a fracture has no proven benefit in men on androgen deprivation therapy

ANSWER: C

Rationale:

This patient has multiple, converging indications for bone-protective pharmacotherapy beyond calcium and vitamin D: a low baseline T-score (-1.6, below -1.0), a prior fragility fracture (wrist fracture after a minor fall), documented progressive bone loss to -2.2 despite supplementation, and prolonged (more than 12 months) androgen deprivation therapy (ADT). In this setting, established agents are zoledronic acid 4 mg intravenously every 12 months or denosumab 60 mg subcutaneously every 6 months; denosumab has a strong evidence base for reducing fracture risk in men on ADT. Initiating one of these agents is the appropriate management.

Option A: Option A is incorrect because calcium and vitamin D alone are not sufficient in a high-risk patient who has already demonstrated progressive bone loss and has a prior fragility fracture; supplementation is foundational but inadequate by itself here.
Option B: Option B is incorrect because ADT-related bone loss is not fully reversible with treatment holidays, and intermittent ADT is a strategy for selected non-metastatic biochemically recurrent disease, not a substitute for bone-targeted therapy in a high-risk patient who needs ongoing castration.
Option D: Option D is incorrect because testosterone supplementation is contraindicated in prostate cancer; it would stimulate tumor growth, and bone protection in this setting is achieved with non-hormonal agents, not testosterone.
Option E: Option E is incorrect because the standard of care in high-risk patients is to initiate bone-protective therapy prophylactically rather than waiting for a major fracture; vertebral and hip fractures carry substantial morbidity and mortality, and the presence of multiple risk factors here justifies treatment now.

12. A 28-year-old man with isolated hypogonadotropic hypogonadism (low LH, low FSH, low testosterone, intact pituitary on imaging) has been receiving testosterone gel for several years for symptom control. He and his partner now wish to conceive. Which of the following changes in management is most appropriate to restore his fertility?

A) Discontinue testosterone replacement and begin pulsatile GnRH therapy via a portable pump delivering GnRH every 60 to 120 minutes (or alternatively exogenous gonadotropin therapy), because physiologic pulsatile stimulation of the intact pituitary restores LH and FSH secretion and induces spermatogenesis, whereas exogenous testosterone suppresses it
B) Continue testosterone replacement and add a GnRH agonist depot, because combined therapy maximizes intratesticular androgen levels needed for spermatogenesis
C) Increase the testosterone gel dose to raise serum testosterone further, because higher systemic testosterone levels drive spermatogenesis more effectively in hypogonadotropic men
D) Begin a continuous (non-pulsatile) GnRH infusion, because steady receptor occupancy provides the most reliable stimulation of pituitary gonadotropin output for fertility
E) Begin degarelix to block residual GnRH receptor desensitization, allowing the pituitary to recover gonadotropin secretion and restore fertility

ANSWER: A

Rationale:

In isolated hypogonadotropic hypogonadism (HH) with an intact pituitary, the defect is deficient pulsatile GnRH delivery, while the pituitary gonadotrophs themselves are functional. The fertility-restoring strategies are pulsatile GnRH therapy — a portable pump delivering small GnRH doses every 60 to 120 minutes to mimic physiologic hypothalamic secretion, which stimulates LH and FSH and thereby drives intratesticular testosterone production and spermatogenesis — or alternatively exogenous gonadotropin therapy. Critically, exogenous testosterone replacement must be discontinued, because systemic testosterone suppresses pituitary LH and FSH through negative feedback and shuts down intratesticular testosterone and spermatogenesis. Pulsatile GnRH therapy induces spermatogenesis adequate for conception in roughly 75 to 80% of treated HH men.

Option B: Option B is incorrect because continuing testosterone suppresses gonadotropins and spermatogenesis, and a GnRH agonist depot produces continuous (non-pulsatile) receptor occupancy that downregulates the receptor and further suppresses the axis — the opposite of what is needed.
Option C: Option C is incorrect because raising systemic testosterone does not drive spermatogenesis in hypogonadotropic men; spermatogenesis depends on high intratesticular testosterone generated by FSH/LH stimulation, and exogenous testosterone actually suppresses the gonadotropin drive required for sperm production.
Option D: Option D is incorrect because continuous GnRH stimulation causes receptor downregulation and suppression of gonadotropins (the mechanism exploited by agonist depots); only pulsatile delivery maintains gonadotropin secretion and supports fertility.
Option E: Option E is incorrect because degarelix is a GnRH antagonist that blocks the receptor and suppresses gonadotropins; it would deepen the existing deficiency, not restore fertility, and there is no role for it in this setting.

13. Four men with prostate cancer are each on continuous GnRH agonist therapy and ask their oncologists whether they are candidates for intermittent androgen deprivation therapy with treatment holidays. Based on the best available evidence, which of the following patients is the most appropriate candidate for intermittent androgen deprivation therapy?

A) A man with newly diagnosed widely metastatic prostate cancer involving the spine, liver, and multiple nodal sites, currently deriving good symptom relief from continuous therapy
B) A man with castration-resistant prostate cancer whose PSA is rising despite confirmed castrate testosterone levels
C) A man with visceral metastatic disease and a rapidly rising PSA on continuous therapy who has not yet reached a PSA nadir
D) A man who had a radical prostatectomy 3 years ago, now has a biochemical recurrence (rising PSA) with no radiographic evidence of metastases, and has reached an undetectable PSA nadir on androgen deprivation therapy
E) A man with extensive bone metastases and pathologic fractures who is highly symptomatic and dependent on continuous testosterone suppression for pain control

ANSWER: D

Rationale:

The strongest evidence for intermittent androgen deprivation therapy (ADT) — demonstrating overall survival comparable to continuous ADT — applies to men with biochemically recurrent, non-metastatic prostate cancer who achieve a good PSA nadir on therapy. The candidate in option D fits precisely: PSA-only recurrence after prostatectomy, no radiographic metastases, and an undetectable PSA nadir on ADT. In this setting, intermittent therapy allows partial testosterone recovery during off-cycles, which can mitigate some long-term adverse effects of sustained hypogonadism (metabolic syndrome, bone loss, fatigue, sexual dysfunction) without compromising survival.

Option A: Option A is incorrect because widely metastatic disease is generally managed with continuous ADT; the comparable-survival evidence for intermittent therapy does not extend to high-volume metastatic disease, and this patient is benefiting from continuous suppression.
Option B: Option B is incorrect because castration-resistant prostate cancer (progression despite castrate testosterone) requires continued testosterone suppression plus additional therapies; intermittent ADT with planned testosterone recovery is inappropriate when the disease is already progressing at castrate levels.
Option C: Option C is incorrect because intermittent ADT protocols require first achieving a confirmed PSA nadir before any treatment holiday; a patient with visceral metastases and a rising PSA who has not reached a nadir is not a candidate.
Option E: Option E is incorrect because a highly symptomatic patient with extensive bone metastases and pathologic fractures depends on continuous testosterone suppression for disease and pain control; allowing testosterone recovery during off-cycles would risk symptomatic flare and is not appropriate.

14. A 65-year-old man receiving goserelin 10.8 mg every 3 months for prostate cancer is seen by a new nurse who administers the implant. Three weeks later his testosterone, previously well suppressed, is found to be 130 ng/dL, and review reveals the implant was placed deep into muscle rather than into the subcutaneous tissue of the anterior abdominal wall. Which of the following best explains the loss of testosterone suppression?

A) Intramuscular placement accelerates polymer degradation, causing the entire dose to be released within 48 hours and leaving no drug to maintain suppression for the remainder of the interval, but this has no effect on the depth of suppression achieved
B) Goserelin is designed for subcutaneous placement in the anterior abdominal wall, where the copolymer matrix degrades at a controlled rate; intramuscular placement disrupts the controlled-release kinetics and can produce unpredictable, often inadequate, drug delivery and loss of testosterone suppression
C) Intramuscular placement causes the implant to be eliminated unchanged in the urine because muscle tissue cannot hydrolyze the copolymer matrix, so no drug is released at all
D) The loss of suppression is unrelated to the route of placement; goserelin commonly fails at 3 weeks regardless of technique, and the implant should be removed and replaced with oral relugolix
E) Intramuscular placement increases the systemic bioavailability of goserelin, producing supratherapeutic levels that paradoxically stimulate testosterone secretion through receptor upregulation

ANSWER: B

Rationale:

Goserelin is formulated as a biodegradable copolymer implant designed specifically for subcutaneous (SC) placement in the anterior abdominal wall, where the glycolide-lactide matrix degrades at a controlled, predictable rate to release drug evenly across the dosing interval. Correct SC placement is essential: when the implant is inadvertently placed intramuscularly (IM), the different tissue environment disrupts the controlled-release kinetics, producing unpredictable and often inadequate drug delivery. This explains the loss of testosterone suppression (rise to 130 ng/dL) in this patient after IM placement. The clinical lesson is that proper SC technique is a quality-of-care requirement for goserelin.

Option A: Option A is incorrect because, although IM placement disrupts release kinetics, the claim that it has no effect on the depth of suppression is wrong — the consequence in this patient is precisely a loss of adequate suppression (non-castrate testosterone), and the simplistic "entire dose in 48 hours with no effect on suppression" description is not accurate.
Option C: Option C is incorrect because muscle tissue does not cause the implant to be excreted unchanged in the urine; the copolymer still degrades, but at an altered, unpredictable rate — the issue is disrupted kinetics, not zero drug release with renal elimination of the intact implant.
Option D: Option D is incorrect because goserelin does not commonly fail at 3 weeks regardless of technique; this failure is directly attributable to the misplacement, and the appropriate response addresses technique rather than assuming inherent product failure.
Option E: Option E is incorrect because IM placement does not produce supratherapeutic levels that stimulate testosterone through receptor upregulation; GnRH agonists suppress testosterone via receptor downregulation, and the observed problem is underdelivery from disrupted release, not paradoxical stimulation.

15. A 69-year-old man on leuprolide depot for prostate cancer reports frequent, disruptive hot flashes that interfere with sleep and daily function. His cancer is well controlled. He asks whether anything can be done about the hot flashes. Which of the following is the most appropriate pharmacologic option?

A) Begin transdermal estradiol, because estrogen replacement is the most effective treatment for hot flashes and carries no oncologic risk in men with prostate cancer
B) Begin a short course of high-dose testosterone to counteract the hypogonadal symptom of hot flashes while maintaining cancer control
C) Discontinue the leuprolide entirely, because hot flashes indicate that androgen deprivation therapy is no longer tolerable and must be stopped
D) Begin finasteride, because 5-alpha-reductase inhibition reduces hot flashes by restoring dihydrotestosterone signaling in thermoregulatory centers
E) Begin a nonhormonal agent such as venlafaxine or gabapentin (medroxyprogesterone acetate is another option), because these effectively reduce androgen-deprivation hot flashes, while estrogen-based therapy is contraindicated in prostate cancer

ANSWER: E

Rationale:

Hot flashes are the most common symptomatic adverse effect of GnRH-mediated hypogonadism, occurring in 50 to 80% of men on androgen deprivation therapy (ADT). Effective and appropriate options are nonhormonal agents: venlafaxine, gabapentin, or medroxyprogesterone acetate. These reduce hot flash frequency and severity without stimulating the cancer. Importantly, estrogen-based hot flash therapy, although effective for vasomotor symptoms in other contexts, is contraindicated in prostate cancer patients.

Option A: Option A is incorrect because estrogen-based therapy is contraindicated in prostate cancer; the claim that it carries no oncologic risk in these men is wrong, which is exactly why nonhormonal agents are preferred.
Option B: Option B is incorrect because high-dose testosterone would stimulate prostate cancer growth and directly undermine the goal of ADT; it cannot be used to treat hot flashes in this setting.
Option C: Option C is incorrect because hot flashes are a manageable adverse effect and do not mandate discontinuing effective cancer therapy; symptomatic treatment with nonhormonal agents allows ADT to continue.
Option D: Option D is incorrect because finasteride is not a treatment for ADT-related hot flashes; 5-alpha-reductase inhibition does not relieve vasomotor symptoms in this context, and the premise about restoring dihydrotestosterone signaling is incorrect, as the patient is already profoundly androgen-deprived by design.

16. A 75-year-old man with newly diagnosed advanced prostate cancer requiring androgen deprivation therapy has a history of myocardial infarction 3 months ago, heart failure with reduced ejection fraction, and a prior stroke. His cardiologist is concerned about cardiovascular risk from androgen deprivation therapy. Which of the following choices best reflects appropriate, evidence-informed agent selection for this patient, and the reasoning behind it?

A) Leuprolide depot, because long-acting agonist depots produce more stable testosterone suppression that reduces cardiovascular events compared with oral agents in men with established heart disease
B) Bicalutamide monotherapy, because avoiding pituitary-level suppression eliminates the cardiovascular risk associated with low testosterone while still controlling the cancer
C) Oral relugolix, because in men with established cardiovascular disease an oral GnRH antagonist offers a more favorable cardiovascular profile than a GnRH agonist depot, with faster testosterone recovery and avoidance of agonist-associated metabolic effects, while still achieving effective castration
D) Any GnRH agonist depot, because the choice of androgen deprivation agent has no bearing on cardiovascular outcomes; cardiovascular risk depends solely on the degree of testosterone suppression, which is identical across all agents
E) Degarelix is absolutely required and relugolix must be avoided, because only injectable antagonists have any cardiovascular benefit and oral antagonists increase cardiovascular risk

ANSWER: C

Rationale:

This patient has multiple high-risk cardiovascular features — recent myocardial infarction, heart failure with reduced ejection fraction, and prior stroke. In men with established cardiovascular disease, a GnRH antagonist is generally preferred over a GnRH agonist depot because of a more favorable cardiovascular profile. Oral relugolix is a reasonable, evidence-informed choice: it achieves effective castration while offering faster testosterone recovery after discontinuation (owing to its short half-life of approximately 25 hours) and avoids some of the sustained metabolic effects associated with agonist depots, factors associated with a lower rate of major adverse cardiovascular events compared with leuprolide. Selecting relugolix here applies the principle that antagonists are favored in high cardiovascular-risk patients.

Option A: Option A is incorrect because long-acting agonist depots do not reduce cardiovascular events relative to antagonists; if anything, agonist depots are associated with greater cardiovascular risk than antagonists in high-risk patients, so this reasoning is backwards.
Option B: Option B is incorrect because bicalutamide monotherapy does not provide adequate testosterone suppression for advanced prostate cancer and is not an appropriate primary ADT strategy; moreover, it raises rather than lowers serum testosterone, and it is not a cardiovascular-risk-reduction strategy.
Option D: Option D is incorrect because the choice of agent does influence cardiovascular outcomes; antagonists and agonists are not equivalent in cardiovascular risk despite producing similar castrate testosterone levels, so the premise that agent choice is irrelevant is wrong.
Option E: Option E is incorrect because oral relugolix is an appropriate antagonist option in high cardiovascular-risk patients and does not increase cardiovascular risk relative to agonists; the claim that only injectable antagonists confer benefit and that relugolix must be avoided is not supported.